Publications

See our presentations on Dravet syndrome and ADOA.

Dravet Syndrome Presentations

Zorevunersen in Children and Adolescents with Dravet Syndrome

The New England Journal of Medicine

March 4, 2026

View Article

Zorevunersen continues to demonstrate potential as a disease-modifying therapy in long-term open-label extension studies of patients with Dravet syndrome​

AES 2025

December 5, 2025

View Presentation

Zorevunersen continues to demonstrate potential as a disease-modifying therapy in long-term open-label extension studies of patients with Dravet syndrome

AES 2025

December 5, 2025

View Poster

Zorevunersen demonstrates disease-modifying potential in patients with Dravet syndrome with increases in seizure-free days, improvements in quality of life, and benefits in overall clinical status

AES 2025

December 5, 2025

View Poster

Spectral electroencephalogram abnormalities across development in patients with Dravet syndrome

AES 2025

December 5, 2025

View Poster

Electrophysiological improvements in patients with Dravet syndrome following treatment with zorevunersen, an investigational antisense oligonucleotide

AES 2025

December 5, 2025

View Poster

Zorevunersen demonstrates disease-modifying potential in patients with Dravet syndrome through durable seizure reduction and continuing improvements in cognition, behavior, and functioning through 36 months of treatment in open-label extension studies

CNS 2025

October 9, 2025

View Poster

Substantial improvements in overall seizure burden and seizure-free days in patients with Dravet syndrome treated with zorevunersen: Results from Phase 1/2a and open‑label extension studies

IEC 2025

September 1, 2025

View Poster

EMPEROR Phase 3 study design: Evaluation of zorevunersen as a potential disease-modifying therapy for Dravet syndrome

IEC 2025

September 1, 2025

View Poster

Zorevunersen demonstrates potential as a disease-modifying therapy in patients with Dravet syndrome through durable seizure reduction and improvements in cognition, behavior, and functioning with up to 36 months of maintenance dosing in open-label extension studies

IEC 2025

August 31, 2025

View Presentation

Zorevunersen demonstrates potential as a disease-modifying therapy in patients with Dravet syndrome through durable seizure reduction and improvements in cognition, behavior, and functioning with up to 24 months of maintenance dosing in open-label extension studies

EPNS 2025

July 10, 2025

View Presentation

Zorevunersen (STK-001) demonstrates potential for disease modification, including reductions in seizures and improvements in cognition and behavior in children and adolescents with Dravet syndrome

AES 2024

December 6, 2024

View Poster

Patients with Dravet syndrome in open-label extension studies of zorevunersen (STK-001) have durable reductions in seizure frequency and ongoing improvements in cognition and behavior

AES 2024

December 6, 2024

View Poster

Small changes on the Vineland-3 are meaningful to caregivers of patients with Dravet syndrome

AES 2024

December 6, 2024

View Poster

Spectral EEG analysis demonstrates decreased slow-wave activity in patients with Dravet syndrome after treatment with zorevunersen (STK-001), an antisense oligonucleotide

AES 2024

December 6, 2024

View Poster

24-Month Analysis of BUTTERFLY A Prospective, Observational Study to Investigate Seizures and Comorbidities in Children and Adolescents with Dravet Syndrome

EEC 2024

September 10, 2024

View Poster

ADOA Presentations

FALCON Natural History Study: Longitudinal Assessment of Functional and Anatomical Changes in OPA1 Autosomal Dominant Optic Atrophy

AAO 2025

October 18, 2025

View Presentation

Flavoprotein fluorescence in the 24-month FALCON natural history study of autosomal dominant optic atrophy: A potential biomarker for mitochondrial dysfunction

ARVO 2025

May 3, 2025

View Presentation

FALCON: A prospective natural history study in patients with OPA1-autosomal dominant optic atrophy (ADOA)

NANOS 2025

March 15, 2025

View Presentation

FALCON: A Prospective Natural History Study of Patients with OPA1-Autosomal Dominant Optic Atrophy (ADOA)

ARVO 2024

May 6, 2024

View Poster

OSPREY: An Open-label Study to Investigate Safety, Tolerability, and Exposure of the Antisense Oligonucleotide (ASO) STK-002 in Patients with OPA1 Autosomal Dominant Optic Atrophy (ADOA)

ARVO 2024

May 6, 2024

View Poster

Mitochondrial Dysfunction in Autosomal Dominant Optic Atrophy (ADOA) Assessed in FALCON, A Non-interventional, Natural History Study

ARVO 2024

May 6, 2024

View Poster

STK-002, an Antisense Oligonucleotide (ASO) for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), is Taken Up by Retinal Ganglion Cells (RGCs) and Upregulates OPA-1 Protein Expression After Intravitreal Administration to Non-human Primates (NHPs)

ASGCT 2022

May 16, 2022

View Presentation

Models of Autosomal Dominant Optic Atrophy (ADOA) using iPSCs and Response to Targeted Augmentation of Nuclear Gene Output (TANGO) Antisense Oligonucleotides (ASOs) Treatment

ARVO 2022

May 2, 2022

View Presentation

Antisense oligonucleotide mediated increase in OPA1 improves mitochondrial function in fibroblasts derived from patients with autosomal dominant optic atrophy (ADOA)

ARVO 2021

May 4, 2021

View Presentation

Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for the treatment of autosomal dominant optic atrophy

ARVO 2020

June 12, 2020

View Presentation

Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for treatment of autosomal dominant optic atrophy

ASGCT 2020

May 12, 2020

View Presentation

Featured Publications

Zorevunersen in Children and Adolescents with Dravet Syndrome

The New England Journal of Medicine

March 4, 2026

View Article

Natural History of Children and Adolescents With Dravet Syndrome: A 24-Month Follow-Up

Neurology

November 14, 2025

View Article

Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome

Science Translational Medicine

August 26, 2020

Read Full Article